A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Emgel Warnings, Precautions, Pregnancy, Nursing, Abuse - Erythromycin
Emgel Warnings, Precautions, Pregnancy, Nursing, Abuse - Erythromycin
WARNINGS
No Information Provided.
PRECAUTIONS
General: For topical use only; not for ophthalmic use. Concomitant
topical acne therapy should be used with caution since a possible cumulative
irritancy effect may occur, especially with the use of peeling, desquamating,
or abrasive agents.
Avoid contact with eyes and all mucous membranes. The use of antibiotic agents
may be associated with the overgrowth of antibiotic-resistant organisms. If
this occurs, discontinue use and take appropriate measures.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Animal studies
to evaluate carcinogenic and mutagenic potential or effects on fertility have
not been performed with erythromycin.
Pregnancy Category B: There was no evidence of teratogenicity
or any other adverse effect on reproduction in female rats fed erythromycin
base (up to 0.25% of diet) before and during mating, during gestation, and through
weaning of two successive litters. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are not always
predictive of human response, this drug should be used in pregnancy only if
clearly needed. Erythromycin has been reported to cross the placental barrier
in humans, but fetal plasma levels are generally low.
Nursing Mothers: It is not known whether topically applied
erythromycin is excreted in human milk. A decision should be made whether to
discontinue nursing or to discontinue the drug, taking into account the importance
of the drug to the mother.
Pediatric Use: Safety and effectiveness in children have
not been established.
top
